Defined as a modern type of production, the process of Biomanufacturing uses both natural and engineered biological systems, such as microorganisms and cell cultures, to produce biomaterials, which can be used on a commercial scale or in medicines, food and beverage processing, and industrial applications.

Biomanufacturing also involves engineering or adding a specific DNA into the plant’s genome that gives it a distinctive feature. The artificial selection for the desired traits can not only result in a variety of different crops, but can also optimize agricultural performances and produce valuable ingredients. Likewise, there has been an improvisation in growing crops that can bloom faster, gives production year-round and can withstand environmental stresses better.

Plant based biomanufacturing includes protein manufacturing processes through recombinant protein production. These proteins include protein biopolymers, industrial proteins and enzymes, and therapeutic proteins. The production processes involve a narrowing diversity of bioreactors for cell, hairy root, microalgae, and moss cultivation. Direct use of cultivated plant cells, whole or minimally processed plants, or plant parts (e.g., seeds, dried leaves) is in development for industrial/bioenergy applications as well as for therapeutics and vaccines and play a vital role in bio-pharmaceutical productions.

Trends of the Plant Based Biomanufacturing Market:

Global plant based biomanufacturing market will report an impressive CAGR in the forecast period, 2022-2026. The market growth can be attributed to the advancing healthcare capabilities to device treatment from plant based elements. Further, increasing number of pipeline products that are a part of plant based biologics is further drive the growth of the global plant based biomanufacturing market in the upcoming 5 years. Also, rising demands for the human biologics, and to make these procedures affordable and less time consuming, the global plant based biomanufacturing market is expected to grow substantially in the next 5 years.

The next generation of biomanufacturing plants has significantly escalated the supply of biologic medicines due to growing awareness among the people regarding its benefit and increasing commercialization and development of pipeline therapy products due to a significant rise in cancer, diabetes, and liver and kidney diseases amongst people. Moreover, a paradigm shift toward the adoption of single-use products such as single-use bio containers and burgeoning funding by the government and private investors for the development of next-generation biomanufacturing facilities is among the factors driving the growth of the market.

Additionally, recent developments in plant expression vectors, downstream processing, and glycoengineering have established plants as a superior alternative to biologics production. As a next best commercial development in the field of biotechnology the global plant based biomanufacturing market is anticipated to register esteemed growth in the future 5 years. The market is segmented by product type, technology, source, end user, competitional landscape and regional distribution. Based on product type, the market is further bifurcated into antibodies, vaccines, proteins, biologics, enzyme, and others. Biologics are anticipated to hold the largest revenue shares of the market and dominate the segment in the next 5 years on the account of changing consumer preferences to more nutritional and herbal products.

Consistent research and advancing plant based medicinal nutrient is also driving the growth of the global plant based biomanufacturing market in the upcoming 5 years. Vaccines are expected to show fastest growing CAGR in the next 5 years on the account of rapidly evolving drug development procedures that have plant based recombinant proteins. Besides, the study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Also, the recent pandemic situation due to COVID-19 has enhanced the healthcare industry inclination toward finding plant based vaccines for the protection against deadly viruses. These factors are actively influencing the growth of the global plant based biomanufacturing market in the future 5 years of forecast until 2026.

Holding the major shares of the global plant based biomanufacturing market are Pfizer, Inc., Aimmune Therapeutics Inc. (Nestle), Medicago, Inc., Kentucky BioProcessing, Inc., iBio, Inc., PlantForm Corporation, Ventria Bioscience Inc., Protalix Biotherapeutics, Inc., Planet Biotechnology Inc., Zea Biosciences Corp., among others. Market players are actively involved in the research and technological development in the product developments. The advanced technology has made it possible for the industry to provide excellent services through plant based biomanufacturing.

Further advancement would aid the market value and brand establishment in the future 5 years. New market players may focus on the research and development to provide options that satisfies the consumer demand as well as benefits the market players in building their brand value. Other competitive strategies include mergers & acquisitions and new product developments.